Zymergen, every mention

mentionsepisodesper episode tap a year for its mentions

Verbatim, from the transcripts: the passages where Zymergen comes up

loading…

▶ 1:10:25 David Friedberg Another good example of this is Zymergen and Ginkgo. 6 times in the scene

▶ 1:10:19 David Friedberg Um, you know, there's a business like, like, Zymergen is a good example, right?

▶ 27:39 Chamath Palihapitiya And, you know, this may be a good jumping off point for, uh, you know, we wanted to talk about Zymergen today.
▶ 38:42 David Sacks I mean, we, you know, if we invest before you have a functional product, it's going to be at a seed valuation, you know, like a 10 cap, ten million dollar valuation, not in the billions, uh, like, you know, like Zymergen, uh, and, you… 2 times in the scene
▶ 47:00 David Friedberg What they're saying is we can, in the case of Zymergen, we've got X number of experiments we can run per day.
▶ 47:59 Chamath Palihapitiya There's a synthetic biology competitor to Zymergen, who I spent a bunch of time with. 2 times in the scene
▶ 52:49 Chamath Palihapitiya The Zymergen IPO, the traditional IPO would have been entirely different if they had to write, if the underwriters were at risk,
▶ 56:44 David Friedberg You guys, let me just give you some specifics on the Zymergen scenario. 4 times in the scene

▶ 1:05:32 Jason Calacanis Tell us about, um, the, the Gink, Ginko Bioworks public offering and the Zemergen IPO?
▶ 1:08:02 David Friedberg So Zymergen, which was, you know, got a bunch of SoftBank money. 3 times in the scene

Turn any episode into a week of clips.